[Recombinant factor VII activated in non-hemophiliac patients with acute severe hemorrhage in the intensive care unit].
Severe hemorrhage is a frequent complication with multiple etiologies and high morbi-mortality observed among critically ill patients. Recombinant Factor VIla (rFVlla) constitutes a new therapeutic alternative. Analyze the evolution in a non-hemophiliac patient group with severe hemorrhage treated with rFVlla. Ten non-hemophiliac patients with severe hemorrhage, five men and five women between 18 and 74 years, were included and treated with rFVIIa. We used a t test for statistic analyses. Significance was set at p < 0.001. Among patients treated with rFVlla, hemorrhage was controlled and the use of blood products was significantly diminished (p < 0.001). Coagulation tests, fibrinogen levels, platelet count and perfusion parameters increased significantly (p < 0.001). rFVIIa is a therapeutic alternative for the treatment of severe hemorrhage not controlled by conventional management.